Future cancer research priorities in the USA: a Lancet Oncology Commission
| Autor: | Dean Ornish, Deborah K. Mayer, Richard Sullivan, Andrew Futreal, Alan Ashworth, Brian D. Kavanagh, Richard L. Wahl, Kelly M. McMasters, Chanita Hughes-Halbert, Timothy M. Pawlik, Rick A. Kittles, James R. Heath, Anna D. Barker, Hossein Jadvar, Stanton L. Gerson, Kenneth C. Anderson, SS Gambhir, Daniel G. Coit, Patricia A. Ganz, Elaine R. Mardis, Sandra L. Wong, Ramy Ibrahim, Brian M. Alexander, Atul J. Butte, Ruth I. Hoffman, Peter Naredi, Cliff Hudis, Christine S. Ritchie, Quynh-Thu Le, Jeffrey Peppercorn, Elizabeth M. Jaffee, Mark M. Davis, Beverly S. Mitchell, Robert B. Diasio, David A. Mankoff, Jeffrey A. Bluestone, David B. Agus, Levi A. Garraway, Sangeeta N. Bhatia, A. Lindsay Frazier, Otis W. Brawley, Nancy E. Davidson, Roshan Bastani, Scott M. Lippman, Alfred Yung, Sally W. Schwarz, Martin G. Pomper, Sumit Gupta, Ronald A. DePinho, Neal J. Meropol, Derek Raghavan, Chi Van Dang, Giulio Draetta, Jedd D. Wolchok |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Technological revolution Biomedical Research Population Big data National Cancer Institute Oncology and Carcinogenesis MEDLINE Commission Medical Oncology 03 medical and health sciences 0302 clinical medicine Rare Diseases Clinical Research Neoplasms Medicine Humans Oncology & Carcinogenesis Precision Medicine education Cancer education.field_of_study business.industry Health Priorities Prevention Precision medicine medicine.disease Health equity National Cancer Institute (U.S.) United States Health Planning 030104 developmental biology Good Health and Well Being Oncology 030220 oncology & carcinogenesis Cancer research business Forecasting |
| Zdroj: | The Lancet. Oncology, vol 18, iss 11 |
| ISSN: | 1474-5488 |
| Popis: | We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|